Search PubMedSearch

PubMed · 8168258

Supporting interoperability between medical knowledge-based systems: experience from pilot implementations.

Abstract

Interoperability may be defined as the ability of knowledge-based systems to function together in a symbiotic manner. Cooperativity implies interoperability but with the added benefit that the output quality of the cooperative network exceeds the overall performance of the participating sub-systems. A number of candidate architectures to support interoperability and cooperativity between medical knowledge-based systems in laboratory medicine domains are now becoming available. Using rapid prototyping techniques, we have demonstrated the feasibility of one of these approaches by carrying out pilot implementations in two unrelated laboratory medicine domains (an internal consistency checking system for validating patients' results in the laboratory and a system for generating alarms and alerts in high dependency units based on laboratory data). The results of this study are discussed in the context of the available techniques so as to provide a basis for further development of cooperative systems in laboratory medicine.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G P Boran, P G Given, J B Grimson, R R O'Moore. 1993-12-15. Supporting interoperability between medical knowledge-based systems: experience from pilot implementations.. https://doi.org/10.1016/0009-8981(93)90089-m

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Multivariate discriminant analysis of biochemical parameters for the differentiation of clinically confounding liver diseases.

We describe a series of studies on the contribution of laboratory medicine to the differential diagnosis of clinically confounding diseases in the field of chronic hepatobiliary diseases. Ascitic cholesterol and lactate dehydrogenase (LD), selected by multivariate discriminant analysis (MDA) from a multitude of serum and ascitic analytes, correctly classified 100% of patients with malignant ascites or non-malignant ascites. In addition, ascitic pseudouridine differentiated hepatocarcinoma (HC) from cirrhotic ascites with a diagnostic effectiveness (overall discrimination power) of 90%. A panel of analytes constituted by serum gamma-glutamyltransferase (GGT), the GGT isoenzyme complexed with low- and very low-density lipoprotein, aspartate aminotransferase, copper, hepatic alkaline phosphatase (AP), the LD-5 isoenzyme and alpha-fetoprotein (AFP), selected by the MDA, correctly classified 93% of about 200 cases of cirrhosis or HC. Finally, MDA also identified an equation, based on serum values of the LD-4/LD-5 and carcinoembryonic antigen/AFP ratios, AP and iron that correctly classified 96% of HC or secondary liver neoplasia cases in 100 patients. This approach based on panels of analytes selected by a sophisticated statistical analysis is a rapid and non-invasive contribution to the differential diagnosis of chronic liver disease including neoplasia.

Chemistry, Clinical